Neutrophil chemotaxis in psoriasis

Area of Science:

• Immunology
• Dermatology
• Cell Biology

Background:

• Psoriasis is a chronic inflammatory skin condition.
• Neutrophil function, including chemotaxis, may be altered in psoriatic patients.
• The role of plasma factors and intracellular signaling in psoriatic neutrophil behavior is not fully understood.

Purpose of the Study:

• To investigate neutrophil chemotaxis in psoriatic patients compared to healthy controls.
• To assess the effect of phosphodiesterase inhibitor treatment on neutrophil chemotaxis.
• To explore the influence of plasma factors from psoriatic patients on neutrophil function.

Main Methods:

• Neutrophil chemotaxis assays were performed on 69 psoriatic patients and 37 healthy subjects.
• Assays included assessment of neutrophils from untreated patients, treated patients, and normal leukocytes incubated with patient plasma.
• Plasma chemoattracting properties were evaluated.

Main Results:

• Neutrophil chemotaxis was significantly enhanced in 52 untreated psoriatic patients.
• Treatment with the phosphodiesterase inhibitor Diphylline normalized neutrophil chemotaxis.
• Plasma from psoriatic patients, especially those with extensive lesions, altered normal leukocyte chemotaxis and exhibited chemoattracting properties.

Conclusions:

• Psoriatic neutrophils exhibit an intrinsic chemotactic abnormality, potentially related to a decreased cyclic AMP/cyclic GMP ratio.
• Plasma factors in psoriasis influence neutrophil chemotaxis, with effects varying based on disease extent.
• These findings suggest a complex interplay between intrinsic neutrophil dysfunction and extrinsic plasma factors in psoriasis pathogenesis.